A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer
Status:
Recruiting
Trial end date:
2024-05-07
Target enrollment:
Participant gender:
Summary
Brigatinib is a medicine that binds to the surface of tumor cells in some cancers and
delivers a dose of chemotherapy directly to the tumor. In this study, participants will be
people with non-small-cell lung cancer (NSCLC for short). The main aim of the study is to
learn if brigatinib stops the tumors from growing, or if the tumors have shrunk or
disappeared, compared to a medicine called alectinib.
At the first visit, the study doctor will check who can take part. Participants who can take
part will be picked for 1 of 2 treatments by chance:
- Brigatinib tablets
- Alectinib capsules
All participants will take brigatinib or alectinib at about the same time every day. They
will continue with treatment throughout the study unless their cancer gets worse, they have
side effects from the treatment, they leave the study for certain reasons, or the study is
stopped.
After stopping treatment, participants will visit the study clinic for a check-up 30 days
later.